Q32 Bio Inc.

Equities

QTTB

US7469641051

Biotechnology & Medical Research

Delayed Nasdaq 10:57:36 2024-03-28 am EDT 5-day change 1st Jan Change
16.6 USD +2.66% Intraday chart for Q32 Bio Inc. -0.73% +47.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Q32 Bio Inc.(NasdaqGM:QTTB) added to NASDAQ Composite Index CI
Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index CI
Q32 Bio Inc. announced that it has received $42 million in funding from a group of investors CI
Q32 Bio Inc. completed the acquisition of Homology Medicines, Inc. from 5AM Venture Management, LLC, Arch Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P. managed by Arch Venture Partners, L.P., Pfizer Inc. and TLS Beta Pte. Ltd. in a reverse merger transaction. CI
North American Morning Briefing : Markets on Hold -2- DJ
Homology Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Neurogene Names Julie Jordan as Chief Medical Officer MT
Q32 Bio Inc. announced that it expects to receive $42 million in funding from a group of investors CI
Homology Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from S&P Global BMI Index CI
North American Morning Briefing : China Trouble -2- DJ
Homology Medicines, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Wall Street Eyes -2- DJ
Baird Downgrades Homology Medicines to Neutral From Outperform, Adjusts Price Target to $1.50 From $9 MT
Homology Medicines, Inc. Approves Reduction in Workforce CI
Homology Medicines, Inc. Approves Reduction in Workforce CI
Transcript : Homology Medicines, Inc. - Special Call
Homology Medicines Announces Plan to Evaluate Strategic Options CI
Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell Microcap Index CI
Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell Microcap Value Index CI
Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 3000E Index CI
Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 3000E Value Index CI
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting CI
Chardan Cuts Price Target on Homology Medicines to $7 From $8, Maintains Buy Rating MT
Homology Medicines, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Q32 Bio Inc.
More charts
Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Q32 Bio Inc. - Nasdaq
  4. News Q32 Bio Inc.
  5. Homology Medicines : Chardan Adjusts Price Target on Homology Medicines to $30 From $32, Maintains Buy Rating